Consensus paper

Management of degenerative cerebellar disorders

W. Ilg, Amy J Bastian, S. Boesch, R. G. Burciu, Pablo A Celnik, J. Claaßen, K. Feil, R. Kalla, I. Miyai, W. Nachbauer, L. Schöls, M. Strupp, M. Synofzik, J. Teufel, D. Timmann

Research output: Contribution to journalArticle

Abstract

Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation.

Original languageEnglish (US)
Pages (from-to)248-268
Number of pages21
JournalCerebellum
Volume13
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Cerebellar Diseases
Cerebellar Ataxia
Consensus
Aminopyridines
Spinocerebellar Degenerations
Speech Therapy
Acetazolamide
Occupational Therapy
Pharmaceutical Preparations
Cerebellum
Therapeutics
Rehabilitation
Learning
Guidelines
Brain

Keywords

  • Cerebellar ataxia
  • Cerebellum
  • Drug therapy
  • Motor rehabilitation
  • Physiotherapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Consensus paper : Management of degenerative cerebellar disorders. / Ilg, W.; Bastian, Amy J; Boesch, S.; Burciu, R. G.; Celnik, Pablo A; Claaßen, J.; Feil, K.; Kalla, R.; Miyai, I.; Nachbauer, W.; Schöls, L.; Strupp, M.; Synofzik, M.; Teufel, J.; Timmann, D.

In: Cerebellum, Vol. 13, No. 2, 2014, p. 248-268.

Research output: Contribution to journalArticle

Ilg, W, Bastian, AJ, Boesch, S, Burciu, RG, Celnik, PA, Claaßen, J, Feil, K, Kalla, R, Miyai, I, Nachbauer, W, Schöls, L, Strupp, M, Synofzik, M, Teufel, J & Timmann, D 2014, 'Consensus paper: Management of degenerative cerebellar disorders', Cerebellum, vol. 13, no. 2, pp. 248-268. https://doi.org/10.1007/s12311-013-0531-6
Ilg, W. ; Bastian, Amy J ; Boesch, S. ; Burciu, R. G. ; Celnik, Pablo A ; Claaßen, J. ; Feil, K. ; Kalla, R. ; Miyai, I. ; Nachbauer, W. ; Schöls, L. ; Strupp, M. ; Synofzik, M. ; Teufel, J. ; Timmann, D. / Consensus paper : Management of degenerative cerebellar disorders. In: Cerebellum. 2014 ; Vol. 13, No. 2. pp. 248-268.
@article{e6caec41c4d74ea486d43e46aa807c71,
title = "Consensus paper: Management of degenerative cerebellar disorders",
abstract = "Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation.",
keywords = "Cerebellar ataxia, Cerebellum, Drug therapy, Motor rehabilitation, Physiotherapy",
author = "W. Ilg and Bastian, {Amy J} and S. Boesch and Burciu, {R. G.} and Celnik, {Pablo A} and J. Claa{\ss}en and K. Feil and R. Kalla and I. Miyai and W. Nachbauer and L. Sch{\"o}ls and M. Strupp and M. Synofzik and J. Teufel and D. Timmann",
year = "2014",
doi = "10.1007/s12311-013-0531-6",
language = "English (US)",
volume = "13",
pages = "248--268",
journal = "Cerebellum",
issn = "1473-4222",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Consensus paper

T2 - Management of degenerative cerebellar disorders

AU - Ilg, W.

AU - Bastian, Amy J

AU - Boesch, S.

AU - Burciu, R. G.

AU - Celnik, Pablo A

AU - Claaßen, J.

AU - Feil, K.

AU - Kalla, R.

AU - Miyai, I.

AU - Nachbauer, W.

AU - Schöls, L.

AU - Strupp, M.

AU - Synofzik, M.

AU - Teufel, J.

AU - Timmann, D.

PY - 2014

Y1 - 2014

N2 - Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation.

AB - Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation.

KW - Cerebellar ataxia

KW - Cerebellum

KW - Drug therapy

KW - Motor rehabilitation

KW - Physiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84896314738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896314738&partnerID=8YFLogxK

U2 - 10.1007/s12311-013-0531-6

DO - 10.1007/s12311-013-0531-6

M3 - Article

VL - 13

SP - 248

EP - 268

JO - Cerebellum

JF - Cerebellum

SN - 1473-4222

IS - 2

ER -